

Remarks


Claims 2 and 5-8 have been amended for clarity so as to overcome the rejections thereof under 35 USC 112 set forth by the Examiner on pages 8-18 of the Action. More particularly, claim 2 has been amended to refer to 'a method of preventing excess NO production in a mammal in need of such prevention comprising administering to said mammal an effective i-NOS inhibiting amount of a compound of formula I'. Claims 5-8 now refer to disease states that are alleviated by the claimed method. No new matter has been added. It is submitted that the foregoing amendment to the claims has obviated this rejection and that it should, therefore, be withdrawn.

Turning to the only other matter discussed in the Action, the election/restriction requirement discussed on pages 2-8 of the Action, Applicants hereby affirm the previous provisional election as described in the first paragraph on page 8 of the Action.

Conclusions

In view of the foregoing, it is submitted that all of the claims, as amended, are now in condition for Allowance. Prompt, favorable action to that effect is earnestly solicited.

Respectfully submitted,


Irving Newman, Reg. No. 22,638
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2785
Telefax (908) 231-2626

Aventis Docket No. ST01033US CNT